DMAC Forex News

DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer

Biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) announced Monday the appointment of Lorianne Masuoka as Chief Medical Officer. Masuoka is a board-certified neurologist with more than 25 years of experience in managing clinical programs from early stage to drug approvals and strategic alliances.

RTTNews | 532 days ago

DiaMedica Therapeutics Says FDA Lifts Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

Biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) announced Wednesday that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS).

RTTNews | 747 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.17175	GBPUSD	1.36114	AUDUSD	0.64997
USDJPY	146.144	USDCAD	1.36649	USDCHF	0.79832

Advertisement

DMAC Forex News

DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer

DiaMedica Therapeutics Says FDA Lifts Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke